US-headquartered venture capital firm Remiges Ventures has closed its second fund at $95m with contributions from investors including pharmaceutical groups EA Pharma, Senju Pharmaceutical and Taiho Pharmaceutical.
Remiges BioPharma Fund II’s limited partners (LPs) also include healthcare-focused investment firm 1Globe Capital.
Taiho committed up to $30m for the fund in 2019. It provided the same amount for Remiges’ first vehicle five years earlier, investing alongside peer Sumitomo Dainippon Pharma, and the fund subsequently closed at $80m in 2017.
Remiges Ventures focuses on innovative pharmaceutical technologies and medical devices developed by Japanese universities. It has teams located in the US city of Seattle and in Tokyo, Japan, and has also formed a biotechnology-themed incubator called RDiscovery.
Tarō Inaba, founding managing partner of Remiges Ventures, said: “We are extremely pleased to close our second fund with six major healthcare companies both in the US and Japan and establish RDiscovery, a new life sciences incubator.
“The team is delighted to be working under our unique cross-border strategy to build new companies based on innovative seed technologies invented by researchers at Japanese academia and investing in early-stage companies globally.”
